What's Happening?
Inflammatix has published data in the Journal of Clinical Microbiology validating the TriVerity Test System, a molecular blood test designed to help emergency department physicians quickly triage patients with suspected acute infection or sepsis. The test demonstrates high accuracy, precision, and ease of use, providing results within 30 minutes. The TriVerity system uses AI/ML to interpret immune response data, offering scores for bacterial and viral infections and illness severity. The FDA granted marketing clearance for TriVerity in January 2025.
Why It's Important?
The validation of the TriVerity Test System is crucial for emergency departments as it enhances the ability to diagnose infections and sepsis rapidly, potentially improving patient outcomes. The test's quick turnaround time and accuracy can lead to more efficient clinical decision-making, reducing the need for extensive diagnostic procedures and enabling timely treatment. This advancement in diagnostics could significantly impact healthcare delivery and patient management in emergency settings.
What's Next?
With the validation of TriVerity, hospitals and health systems may begin integrating the test into their emergency department protocols. The upcoming SEPSIS-SHIELD study will further support its clinical utility, potentially leading to widespread adoption. Inflammatix may continue to develop and refine its diagnostic technologies, expanding their application in other areas of healthcare.
